Analyst Stock Ratings: Oncolytics Biotech Inc. (ONCY), Nova LifeStyle, Inc. (NVFY)

Oncolytics Biotech Inc. (NASDAQ:ONCY) tinted loss of -5.2% (-0.13 points) to US$2.37. The volume of 0.06 Million shares climbed down over an trading activity of 66.34 Million shares. EPS ratio determined by looking at last 12 month figures is -0.83. Over the same time span, the stock marked US$8.55 as its best level and the lowest price reached was US$2.13. The corporation has a market cap of US$38.04 Million.

Oncolytics Biotech Inc. (NASDAQ:ONCY)’s earnings per share has been growing at a 24.4 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at -205.3 percent while most common profitability ratio return on investment (ROI) was 0 percent. The company’s institutional ownership is monitored at 2.5 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 2 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 1 think it is Hold. Recently, analysts have updated the overall rating to 1.8. 2 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

Nova LifeStyle, Inc. (NASDAQ:NVFY) is worth US$27.55 Million and has recently risen 0.54% to US$1. The latest exchange of 0.07 Million shares is below its average trading activity of 44.16 Million shares. The day began at US$0 but the price moved to US$0 at one point during the trading and finally capitulating to a session high of US$0. The stock tapped a 52-week high of US$3 while the mean 12-month price target for the shares is US$0.

Currently, the stock carries a price to earnings ratio of 3.83, a price to book ratio of 0.39, and a price to sales ratio of 0.28. For the past 5 years, the company’s revenue has grown 9.9%, while the company’s earnings per share has grown -2.5%. With an institutional ownership near 4%, it carries an earnings per share ratio of 0.26.